AdultPediatricDosage Forms & Strengths injection, prefilled glass syringe 10mg/0.1mL (Humira) 10mg/0.2mL (Humira, Abrilada, Hyrimoz) 20mg/0.2mL (Humira) 20mg/0.4mL (Humira, Amjevita, Cyltezo, Abrilada) 40mg/0.4mL (Humira) 40mg/0.8mL (Humira, Cyltezo, Abrilada, Amjevita, Hadlima, Hyrimoz, Idacio, Yusimry) 80mg/0.8mL (Humira) injection, prefilled syringe/pen 20mg/0.4mL (Amjevita, Hulio) 40mg/0.4mL (Humira) 40mg/0.8mL (Humira, Abrilada, Amjevita, Hadlima, Hulio, Hyrimoz, Idacio) 80mg/0.8mL (Humira) injection, prefilled autoinjector 40mg/0.8 mL (Amjevita, Yusimry) injection, vial 40mg/0.8mL (Humira) Biosimilars to Humira Abrilada (adalimumab-afzb) Amjevita (adalimumab-atto) Cyltezo (adalimumab-adbm) Hadlima (adalimumab-bwwd) Hulio (adalimumab-fkjp) Hyrimoz (adalimumab-adaz) Idacio (adalimumab-aacf) Yusimry (adalimumab-aqvh) Rheumatoid Arthritis Indicated for the treatment of moderate-to-severe active rheumatoid arthritis 40 mg SC q2wk Dosing considerations May be administered as monotherapy or combined with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs) If not taken with concomitant methotrexate, additional benefit may be derived from increasing frequency to 40 mg qWeek or increasing dose to 80 mg every other week Psoriatic Arthritis Indicated for the treatment of active psoriatic arthritis 40 mg SC q2wk Dosing considerations May be administered as monotherapy or combined with methotrexate or other nonbiologic DMARDs If not taken with concomitant methotrexate, additional benefit may be derived from increasing frequency to 40 mg qWeek or increasing dose to 80 mg every other week Ankylosing Spondylitis Indicated for reduction of signs and symptoms of active ankylosing spondylitis 40 mg SC q2wk Dosing considerations May be administered as monotherapy or combined with methotrexate or other nonbiologic DMARDs If not taken with concomitant methotrexate, additional benefit may be derived from increasing frequency to 40 mg qWeek or increasing dose to 80 mg every other week Plaque Psoriasis Indicated for treatment of moderate-to-severe chronic plaque psoriasis (Ps) in candidates for systemic therapy or phototherapy and when systemic therapies are inappropriate 80 mg SC once, then, after 1 week, 40 mg SC q2wk Use in moderate to severe chronic Ps beyond one year has not been evaluated in controlled clinical studies Humira prescribing information includes patients with moderate-to-severe fingernail psoriasis Crohn Disease Indicated for reduction of signs and symptoms and induction and maintenance of clinical remission in moderately to severely active Crohn disease (CD) with inadequate response to conventional therapy May be used in patients who have lost response to or are intolerant of infliximab Induction: 160 mg SC either as 4 injections of 40 mg on day 1 or as 2 injections of 40 mg daily on 2 consecutive days, then 80 mg SC 2 weeks later (day 15) Maintenance (beginning Week 4 [Day 29]): 40 mg SC q2wk Use in CD beyond 1 yr has not been evaluated in controlled clinical studies Ulcerative Colitis Indicated for patients unresponsive to immunosuppressants (eg, corticosteroids, azathioprine, 6-mercaptopurine [6-MP]) Induction: 160 mg SC either as 4 injections of 40 mg on day 1 or as 2 injections of 40 mg daily on 2 consecutive days, then 80 mg SC 2 weeks later (day 15) Maintenance (beginning Week 4 [Day 29]): 40 mg SC q2wk Continue maintenance dose only if evidence of clinical remission is apparent by 8 weeks of therapy Limitations of use: Effectiveness not established in patients who have failed or were intolerant to TNF blockers Hidradenitis Suppurativa Humira, Abrilada, Cyltezo, Hadlima, Hyrimoz, Hulio, Yusimry only Indicated for treatment of moderate-to-severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease) Induction Day 1: 160 mg SC (given in 1 day or split over 2 consecutive days) Day 15: 80 mg SC Maintenance Beginning Day 29: 40 mg SC qWeek or 80 mg SC every other week Uveitis Humira, Cyltezo, Hadlima only Indicated for treatment of noninfectious intermediate, posterior, and panuveitis in adults 80 mg SC once, then, after 1 week, 40 mg SC q2wk Behcet's Disease (Orphan) Orphan designation for treatment of Behcet's disease Sponsor Mucora; 32b Eisenberg St; Rehovot 7628810 Israel Dosing Considerations Cyltezo is interchangeable with Humira Limitations of use UC: Effectiveness not established in patients who have failed or were intolerant to TNF blockers Dosage Forms & Strengths injection, prefilled glass syringe 10mg/0.1mL (Humira) 10mg/0.2mL (Humira, Abrilada, Hyrimoz) 20mg/0.2mL (Humira) 20mg/0.4mL (Humira, Amjevita, Cyltezo, Abrilada) 40mg/0.4mL (Humira) 40mg/0.8mL (Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hyrimoz, Idacio, Yusimry) 80mg/0.8mL (Humira) injection, prefilled syringe/pen 20mg/0.4mL (Amjevita, Hulio) 40mg/0.4mL (Humira) 40mg/0.8mL (Humira, Abrilada, Amjevita, Hadlima, Hulio, Hyrimoz, Idacio) 80mg/0.8mL (Humira) injection, prefilled autoinjector 40mg/0.8 mL (Amjevita, Yusimry) injection, vial 40mg/0.8mL (Humira) Biosimilars to Humira Abrilada (adalimumab-afzb) Amjevita (adalimumab-atto) Cyltezo (adalimumab-adbm) Hadlima (adalimumab-bwwd) Hulio (adalimumab-fkjp) Hyrimoz (adalimumab-adaz) Idacio (adalimumab-aacf) Yusimry (adalimumab-aqvh) Juvenile Idiopathic Arthritis Indicated for reduction of signs and symptoms of moderately-to-severely active polyarticular juvenile idiopathic arthritis May be administered with methotrexate, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics Humira, Cyltezo, or Hulio <2 years or <10 kg: Safety and efficacy not established ≥2 years <15 kg: No dosage forms available for weight-based dosing ≥2 years 15 kg to <30 kg: 20 mg SC q2wk ≥30 kg: 40 mg SC q2wk Hadlima, Abrilada, or Amjevita <2 years or <10 kg: Safety and efficacy not established ≥2 years 10 to <15 kg: 10 mg SC q2wk 15 to <30 kg: 20 mg SC q2wk ≥30 kg: 40 mg SC q2wk Only dosage form that allows weight-based dosing for pediatric patients <30 kg is the single-dose glass vial for institutional use only Hyrimoz <2 years: Safety and efficacy not established ≥2 years 10 to <15 kg: 10 mg SC q2wk 15 to <30 kg: No dosage form allows for weight-based dosing ≥30 kg: 40 mg SC q2wk Idacio, Yusimry ≥2 years and ≥30 kg: 40 mg SC q2wk Pediatric Crohn Disease Indicated to reduce signs and symptoms, and achieve and maintain clinical remission in pediatric patients with moderately to severely active Crohn disease who have had an inadequate response to corticosteroids or immunomodulators (eg, azathioprine, 6-mercaptopurine, methotrexate) <6 years: Safety and efficacy not established ≥6 years (17 to <40 kg) Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio Induction: 80 mg SC on Day 1 (administer as two 40-mg injections in 1 day); THEN 2 weeks later (Day 15) give 40 mg Maintenance (beginning Week 4 [Day 29]): 20 mg SC q2wk ≥6 years (≥40 kg) Humira, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry Induction: 160 mg SC on Day 1 (administer as four 40-mg injections in 1 day or as two 40-mg injection per day for 2 consecutive days); THEN 2 weeks later (Day 15) give 80 mg (as two 40-mg injections in 1 day) Maintenance (beginning Week 4 [Day 29]): 40 mg SC q2wk Ulcerative Colitis Humira only Indicated for moderately to severely active Ulcerative colitis in patients aged ≥5 years <5 years: Safety and efficacy not established ≥5 years (20 to <40 kg) Days 1-15 Day 1: 80 mg SC Day 8: 40 mg SC Day 15: 40 mg SC Maintenance (beginning Week 4 [Day 29]) 40 mg SC q2Weeks, OR 20 mg SC qWeek ≥5 years (>40 kg) Days 1-15 Day 1: 160 mg SC (single dose or split over 2 consecutive days) Day 8: 80 mg SC Day 15: 80 mg SC Maintenance (beginning Week 4 [Day 29]) 80 mg SC q2Weeks, OR 40 mg SC qWeek Uveitis Humira only Indicated for treatment of noninfectious intermediate, posterior, and panuveitis in patients aged ≥2 years <2 years or <10 kg: Safety and efficacy not established ≥2 years 10 to <15 kg: 10 mg SC q2wk 15 to <30 kg: 20 mg SC q2wk ≥30 kg: 40 mg SC q2wk Hidradenitis Suppurativa Humira only Indicated for treatment of moderate-to-severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease) in adolescents aged ≥12 yr who weigh at least 30 kg <12 years: Safety and efficacy not established ≥12 years 30 kg to <60 kg Induction: 80 mg SC on Day 1, then 40 mg SC 1 week later (Day 8) Maintenance (beginning Day 29): 40 mg SC q2weeks ≥60 kg Induction: 160 mg SC on Day 1 (given in 1 day or split over 2 consecutive days), then 80 mg SC 2 weeks later (Day 15) Maintenance (beginning Day 29): 40 mg SC qWeek Dosing Considerations Cyltezo is interchangeable with Humira Limitations of use UC: Effectiveness not established in patients who have failed or were intolerant to TNF blockers Interaction CheckerEnter a drug name and adalimumabNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)upadacitinibadalimumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.Serious - Use Alternative (73)abataceptabatacept, adalimumab. Mechanism: pharmacodynamic synergism. Contraindicated. Increased risk of serious infection.alefaceptadalimumab and alefacept both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.anakinraadalimumab and anakinra both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.anthrax vaccineadalimumab decreases effects of anthrax vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.antithymocyte globulin equineadalimumab and antithymocyte globulin equine both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.antithymocyte globulin rabbitadalimumab and antithymocyte globulin rabbit both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.axicabtagene ciloleuceladalimumab, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.azathioprineadalimumab and azathioprine both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.baricitinibbaricitinib, adalimumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.basiliximabadalimumab and basiliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.BCG vaccine liveadalimumab decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.brexucabtagene autoleuceladalimumab, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.canakinumabadalimumab and canakinumab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.certolizumab pegoladalimumab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.ciltacabtagene autoleuceladalimumab, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.cyclosporineadalimumab and cyclosporine both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.diphtheria & tetanus toxoidsadalimumab decreases effects of diphtheria & tetanus toxoids by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.diphtheria & tetanus toxoids/ acellular pertussis vaccineadalimumab decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccineadalimumab decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.etanerceptadalimumab and etanercept both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.everolimusadalimumab and everolimus both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.glatirameradalimumab and glatiramer both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.golimumabadalimumab and golimumab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.hepatitis A vaccine inactivatedadalimumab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.hepatitis a/b vaccineadalimumab decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.hepatitis a/typhoid vaccineadalimumab decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.hepatitis b vaccineadalimumab decreases effects of hepatitis b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.human papillomavirus vaccine, nonavalentadalimumab decreases effects of human papillomavirus vaccine, nonavalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.human papillomavirus vaccine, quadrivalentadalimumab decreases effects of human papillomavirus vaccine, quadrivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.hydroxychloroquine sulfateadalimumab and hydroxychloroquine sulfate both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.idecabtagene vicleuceladalimumab, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.infliximabadalimumab and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.influenza virus vaccine